Skip to content

Study of Axillary Skin Temperature as a Marker of Ovulation

Pilot Study of Measuring Axillary Skin Temperature, Using DuoFertility, as a Marker of Ovulation in 10 Women of Childbearing Age

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01360684
Enrollment
10
Registered
2011-05-26
Start date
2010-07-31
Completion date
2015-01-31
Last updated
2018-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Infertility is the most common reason women (aged 20-45yrs)see their GP, affecting 1 in 7 couples. Measuring basal body temperature is a technique that has been used since the 1930's to attempt to predict ovulation. Current NICE guidelines don't recommend the use of BBT charts to predict ovulation, as it has not been established to reliably confirm ovulation. The DuoFertility sensor a CE marked Class la device provides a continuous accurate measure of axilla temperature whilst worn under the arm. The investigators plan to compare the temperature measurements of the DuoFertility sensor with the gold standard transvaginal ultrasound scan obtained during 10 infertile women's menstrual cycles, up to 10 cycles per women. The investigators aim to investigate if continuous axillary skin temperature measurement obtained from the DuoFertility sensor, provides comparable results for identifying the occurrence of ovulation as the gold standard transvaginal ultrasound scan.

Interventions

None listed

Sponsors

Cambridge Temperature Concepts
CollaboratorINDUSTRY
Joanne Outtrim
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 44 Years
Healthy volunteers
Yes

Inclusion criteria

* Participant is willing and able to give informed consent for participation * Females aged 18 to 44 years. * Referred with infertility to the Reproductive Medicine Clinic, Rosie Hospital * Have a body mass index (BMI) above 19 and below 29 * Regular menstrual cycles, i.e. no greater than 7 days difference between the shortest and longest cycle in the last 6 months * Minimum menstrual cycle 21 days * Maximum menstrual cycle 35 days * Willing to wear a DuoFertility sensor continuously for 8 to 10 menstrual cycles; * Willing to attend Rosie Hospital up to 5 times per cycle for TVS and blood tests * Willing to perform twice daily LH urine tests at home from day 8 of cycle till positive * Normal pelvic ultrasound and blood results obtained during screening tests

Exclusion criteria

* Aged younger than 18 years, or older than 44 years * Have a BMI less than 18 or greater than 29 * Any diagnosed systemic illnesses, including but not restricted to thyroid disease, diabetes or inflammatory diseases * Polycystic ovary disease * Endometriosis or other pelvic pathology (including proven tubal disease) * Taking steroids, including oral contraceptives or anti inflammatory drugs

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026